Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by inforcashon Apr 01, 2008 9:43pm
91 Views
Post# 14928701

RE: Bioracle

RE: BioracleBioracle,

I also feel your pain, however I see the forest beyond the trees. Big picture: unless something is stinking with the confirmatory trial, this is a great story. the greatest part about it is that the price is cheap for the taking! Honestsly, if the price hits $4 before bouncing back I will only be upset b/c I didn't but at the bottom! I would suggest we all write/call Andrea to get the lowdown on the trial and possible strategic outcomes. Again, I emphasize the board was tight lipped about everything, so I interpret the last PR as a msg to us shareholders to chill out and be patient.

Saurus,

Where did you hear QC controls 6% of shares? At the AGM the board mentioned QC took 6% of the PP, but made no mention about the rest of the shares already on the market...At 44% shareholders present--by proxy or not--there must have been a few big players in the room. The other 56% obviously weren't as concerned about the recent news as this board seems to be...Did anyone notice that only National Bank seemed to want to ask pertinant questions.

IFC
Bullboard Posts